Literature DB >> 1558968

Anticoagulant and fibrinolytic activities are promoted, not retarded, in vivo after thrombin generation in the presence of a monoclonal antibody that inhibits activation of protein C.

F B Taylor1, H Hoogendoorn, A C Chang, G Peer, M E Nesheim, R Catlett, D C Stump, A R Giles.   

Abstract

This study examines the assumption that both the anticoagulant and fibrinolytic activity that follow the generation of thrombin induced by infusion of factor Xa/PCPS are due to generation of activated protein C. Untreated controls or animals given unrelated antibody were compared with animals pretreated with a specific monoclonal antibody to protein C (HPC4). Compared with untreated controls excess HPC4 substantially reduced the level of protein C activation as observed by protein C immunoblotting and enzyme-linked immunosorbent assay for antitrypsin/activated protein C complexes. Despite this, the anticoagulant activity as reflected by the decline of factors Va and VIIIa levels (as observed by coagulation assays and by factor V immunoblotting) was significantly greater than controls. The fibrinolytic activity (as observed by assays of tissue plasminogen activator, D-Dimer, alpha 2-antiplasmin) also was significantly greater than controls. We conclude that neutralization of the protein C anticoagulant system while resulting in a significantly more intense coagulant response to Xa/PCPS does not preclude inactivation of factors Va and VIIIa and the full expression of the fibrinolytic response. We conclude further that after thrombin generation in vivo, protein C activation is not a prerequisite for the promotion of the fibrinolytic response previously observed, and that the inactivation of factors Va/VIIIa may be mediated by enzymes other than activated protein C. The reduction in alpha 2-antiplasmin levels in association with increased tissue plasminogen activator activity suggests that plasmin is a likely candidate.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1558968

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates.

Authors:  S R Hanson; J H Griffin; L A Harker; A B Kelly; C T Esmon; A Gruber
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

2.  Alpha-2-macroglobulin functions as an inhibitor of fibrinolytic, clotting, and neutrophilic proteinases in sepsis: studies using a baboon model.

Authors:  J P de Boer; A A Creasey; A Chang; J J Abbink; D Roem; A J Eerenberg; C E Hack; F B Taylor
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

Review 3.  Lessons from the aprotinin saga: current perspective on antifibrinolytic therapy in cardiac surgery.

Authors:  Masahiro Ide; Daniel Bolliger; Taro Taketomi; Kenichi A Tanaka
Journal:  J Anesth       Date:  2009-12-29       Impact factor: 2.078

4.  Disseminated intravascular coagulation - what can we do?

Authors:  Cheng-Hock Toh; Julien M H Toh; Simon T Abrams
Journal:  Hemasphere       Date:  2019-06-30

5.  In vivo-generated thrombin and plasmin do not activate the complement system in baboons.

Authors:  Ravi S Keshari; Robert Silasi; Cristina Lupu; Fletcher B Taylor; Florea Lupu
Journal:  Blood       Date:  2017-10-11       Impact factor: 25.476

Review 6.  Current Pathological and Laboratory Considerations in the Diagnosis of Disseminated Intravascular Coagulation.

Authors:  Cheng Hock Toh; Yasir Alhamdi; Simon T Abrams
Journal:  Ann Lab Med       Date:  2016-11       Impact factor: 3.464

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.